RALOX as Second Line Treatment for Advanced Malignant Biliary System Tumor
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study was to explore the safety and efficacy of raltitrexed combined with
oxaplatin as second line treatment for advanced malignant biliary system tumor.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University